Use the hyperlinks, where available to access additional clinical trial information.
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Blueprint Medicines Corporation
Participants enrolled in this trial will be randomized into two groups. In the experimental group, participants will receive oral Avapritinib tablets, dosed at 300 mg once daily, continuously. In the comparator group, participants will receive oral Regorafenib tablets, dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).